Anika Therapeutics, Inc. (ANIK)
Automate Your Wheel Strategy on ANIK
With Tiblio's Option Bot, you can configure your own wheel strategy including ANIK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ANIK
- Rev/Share 7.3828
- Book/Share 10.3796
- PB 1.0694
- Debt/Equity 0.1714
- CurrentRatio 5.7264
- ROIC -0.0947
- MktCap 159189540.0
- FreeCF/Share -0.2344
- PFCF -47.5051
- PE -2.7967
- Debt/Assets 0.1335
- DivYield 0
- ROE -0.3277
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ANIK | B. Riley Securities | -- | Buy | -- | $21 | April 17, 2025 |
News
Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Matt Hall - Director, Corporate Development & Investor Relations Cheryl Blanchard - President & Chief Executive Officer Steve Griffin - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants Anderson Schock - B. Riley Securities Mike Petusky - Barrington Research Jim Sidoti - Sidoti & Company.
Read More
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.09. This compares to loss of $0.31 per share a year ago.
Read More
Anika Reports First Quarter 2025 Financial Results
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
First Quarter 2025 Commercial Channel revenue up 18% Integrity ™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025.
Read More
Is the Options Market Predicting a Spike in Anika Therapeutics Stock?
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ANIK stock based on the movements in the options market lately.
Read More
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
Read More
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
Read More
Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard, President and CEO of Anika, will present at the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego on Monday, March 10, 2025 at 2:30pm PT / 5:30pm ET. Management will also participate in one-on-one investor meetings throughout the event.
Read More
About Anika Therapeutics, Inc. (ANIK)
- IPO Date 1993-05-03
- Website https://www.anikatherapeutics.com
- Industry Medical - Devices
- CEO Dr. Cheryl Renee Blanchard Ph.D.
- Employees 288